Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 9—September 2015
Emerging Infections Program
Emerging Infections Program

Training in Infectious Disease Epidemiology through the Emerging Infections Program Sites

Duc VugiaComments to Author , James I. Meek, Richard Danila, Timothy F. Jones, William Schaffner, Joan Baumbach, Sarah Lathrop, Monica M. Farley, Melissa Tobin-D’Angelo, Lisa Miller, Lee H. Harrison, Nancy M. Bennett, Paul R. Cieslak, Matthew L. Cartter, and Arthur L. Reingold
Author affiliations: California Emerging Infections Program (EIP), California Department of Public Health, Richmond, California, USA (D.J. Vugia) and University of California, Berkeley, California, USA (A.L. Reingold); Connecticut EIP, Yale School of Public Health, New Haven, Connecticut, USA (J.I. Meek), and Connecticut Department of Public Health, Hartford, Connecticut, USA (M.L. Cartter); Minnesota EIP, Minnesota Department of Health, St. Paul, Minnesota, USA (R.N. Danila); Tennessee EIP, Tennessee Department of Health (T.F. Jones) and Vanderbilt University (W. Schaffner), Nashville, Tennessee, USA; New Mexico EIP, New Mexico Department of Health, Santa Fe, New Mexico, USA (J. Baumbach), and University of New Mexico, Albuquerque, New Mexico, USA (S. Lathrop); Georgia EIP, Emory University School of Medicine (M.M. Farley), Atlanta Veterans Affairs Medical Center (M.M. Farley), and Georgia Department of Public Health (M. Tobin-D’Angelo), Atlanta, Georgia, USA; Colorado EIP, Colorado Department of Public Health and Environment, Denver, Colorado, USA (L. Miller); Maryland EIP, Johns Hopkins University, Baltimore, Maryland, USA (L.H. Harrison); New York EIP, University of Rochester Medical Center, Rochester, New York, USA (N.M. Bennett); Oregon EIP, Oregon Health Authority, Portland, Oregon, USA (P.R. Cieslak).

Main Article


Examples of surveillance activities and epidemiologic projects involving trainees, Emerging Infections Program sites, United States, 1995–2014

Surveillance and epidemiologic projects
A. Invasive bacterial diseases
a. Invasive pneumococcal disease
b. Pneumococcal conjugate vaccine effectiveness
c. Pneumococcal carriage
d. Invasive group B streptococcal disease
e. Invasive group A streptococcal disease
f. Neisseria meningitidis infections
B. Foodborne diseases
a. Salmonella infections
b. Salmonella antibiotic resistance
c. Shigella infections
d. Campylobacter infections
e. Shiga toxin–producing Escherichia coli (STEC), O157, and non-O157
f. Cryptosporidium infections
C. Health care–associated infections
a. Methicillin-resistant Staphylococcus aureus (MRSA) infections
b. Clostridium difficile infections
D. Influenza
a. Influenza surveillance
b. Influenza A(H1N1) hospitalizations
c. Guillain-Barré syndrome surveillance
E. Other diseases or conditions
a. Unexplained illness and death surveillance
b. Fungal infection surveillance
c. Tickborne disease surveillance
d. Acute/chronic liver disease surveillance
e. Encephalitis etiology
f. Human papillomavirus vaccine effectiveness

Main Article

Page created: August 12, 2015
Page updated: August 12, 2015
Page reviewed: August 12, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.